Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Repayments: 2019-2025

  • BridgeBio Pharma's Long-Term Debt Repayments fell 3.05% to $459.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 billion, marking a year-over-year change of. This contributed to the annual value of $473.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that BridgeBio Pharma reported Long-Term Debt Repayments of $459.0 million as of Q1 2025, which was down 3.05% from $473.4 million recorded in Q1 2024.
  • Over the past 5 years, BridgeBio Pharma's Long-Term Debt Repayments peaked at $473.4 million during Q1 2024, and registered a low of $106.0 million during Q4 2021.
  • Its 2-year average for Long-Term Debt Repayments is $466.2 million, with a median of $466.2 million in 2024.
  • Data for BridgeBio Pharma's Long-Term Debt Repayments shows a maximum YoY decreased of 3.05% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows BridgeBio Pharma's Long-Term Debt Repayments stood at $106.0 million in 2021, then reached $473.4 million in 2024, then fell by 3.05% to $459.0 million in 2025.
  • Its Long-Term Debt Repayments stands at $459.0 million for Q1 2025, versus $473.4 million for Q1 2024 and $106.0 million for Q4 2021.